Who Can Use Wegovy as a Weight Loss Treatment in Maidstone?
Wegovy (semaglutide) is a prescription only medicine supplied following a clinical consultation. It is intended for adults aged 18 and above with a BMI ≥30 or ≥27 with weight-related comorbidities such as hypertension, dyslipidaemia, sleep apnoea, cardiovascular disease or type 2 diabetes.
Our Maidstone pharmacy team conducts a comprehensive assessment, reviewing medical history, current medications, and readiness for lifestyle changes. Wegovy should not be used during pregnancy or breastfeeding and may not be suitable for people with certain thyroid conditions. Stop Wegovy at least 2 months before planning a pregnancy.
We serve patients across the Maidstone borough, including Loose, Bearsted, Tovil, and surrounding Kent areas, supporting those who have struggled to achieve results with supervised diet and exercise alone.
How Effective Is Wegovy?
- Clinical trials report an average weight reduction of up to 15% over 68 weeks in adults with obesity.
- Semaglutide mimics the GLP-1 hormone, enhancing satiety and regulating appetite signals.
- Reduces cravings and helps manage emotional eating by moderating hunger-driven responses.
- Slows gastric emptying, prolonging post-meal fullness and naturally limiting calorie intake.
- Improves portion control and encourages mindful eating habits for sustainable results.
- Optimal results occur when combined with a reduced-calorie diet and structured physical activity.
- May help improve appetite control and eating behaviours.
- Provides a non-surgical, clinically validated approach for long-term weight management.
- Supports gradual weight loss when combined with diet and physical activity.
- Continued lifestyle adherence is essential to maintain weight after cessation of therapy.
Comparison with Ozempic and Mounjaro
Feature | Wegovy | Mounjaro | Ozempic |
Active Ingredient | Semaglutide | Tirzepatide | Semaglutide |
Mechanism | GLP-1 only | Dual GLP-1 + GIP | GLP-1 only |
Average Weight Loss | Up to 15% | Up to 20.9% | Up to 14.9% |
Starting Dose | 0.25mg weekly | 2.5mg weekly | 0.25mg weekly |
Maintenance Dose | 2.4mg weekly | 5–15mg weekly | 1mg weekly |
Primary UK Approval | Weight loss | Weight loss & diabetes | Diabetes (off-label) |
Cost (Starting) | £139/month | £179.99/month | Varies |
Injection Frequency | Once weekly | Once weekly | Once weekly |
